Jibran Khan, MD
Internal Medicine · Woonsocket, RINPI 1902803935
Payments from drug & device makers
Across 125 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$433
- Mylan Specialty L.p.$417
- AbbVie$366
- Novo Nordisk$232
- Lilly USA, LLC$206
- Exact Sciences$144
- plus $938 from 21 others
What the payments were for
- Food & beverage$2,72399%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 8 | $433 |
| Mylan Specialty L.p. | 26 | $417 |
| AbbVie(2 entities) | 18 | $366 |
| Novo Nordisk | 13 | $232 |
| Lilly USA, LLC | 5 | $206 |
| Exact Sciences | 6 | $144 |
| Pfizer | 8 | $144 |
| Boehringer Ingelheim | 7 | $122 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $102 |
| Novartis | 4 | $78 |
| Kowa Pharmaceuticals America, Inc. | 4 | $73 |
| AstraZeneca | 3 | $72 |
| Paratek Pharmaceuticals, Inc. | 2 | $44 |
| Davol Inc. | 1 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| USWM, LLC | 1 | $27 |
| Viatris Specialty LLC | 1 | $24 |
| GSK | 1 | $22 |
| Octapharma USA, Inc. | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Sanofi | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,738 in reported general payments places this provider in the 85th percentile of 808 internal medicine providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 77 | $56,790 |
| XareltoRivaroxaban | 23 | $21,120 |
| TrulicityDulaglutide | 19 | $20,706 |
| TrintellixVortioxetine Hydrobromide | 12 | $18,515 |
| XifaxanRifaximin | 21 | $18,455 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $18,223 |
| EntrestoSacubitril/Valsartan | 19 | $16,557 |
| OzempicSemaglutide | 14 | $14,522 |
| FarxigaDapagliflozin Propanediol | 16 | $12,758 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,609 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $8,448 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,789 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $7,043 |
| Atorvastatin Calcium | 401 | $5,680 |
| Arnuity ElliptaFluticasone Furoate | 22 | $5,502 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Prempro | $144 | $59,93890 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $22 | $25,55851 claims |
| Johnson & JohnsonXarelto | $433 | $21,12023 claims |
| Lilly USA, LLCTrulicity | $206 | $20,70619 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $72 | $20,54728 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $17 | $18,51512 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $102 | $18,45521 claims |
| Boehringer IngelheimCombivent Respimat | $122 | $18,22321 claims |
| NovartisEntresto | $78 | $16,55719 claims |
| Novo NordiskOzempic | $232 | $14,52214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 808 internal medicine providers in Rhode Island.
Other internal medicine in Woonsocket
- Greigstone YearwoodWoonsocket$7K
- David FriedEast Greenwich$37.2M
- Gregory AllenCranston$12.2M
- Kathleen GordonJohnston$1.1M
- William BeliveauJohnson$962K
- Scott WilsonCumberland$907K
- Aaron SamuelsProvidence$751K
- Frank D'alessandroLincoln$541K
- Andrew HsuProvidence$409K
- Heinrich ElinzanoProvidence$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.